1071 related articles for article (PubMed ID: 25373449)
1. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
[TBL] [Abstract][Full Text] [Related]
3. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
Zöllner N; Griebsch A; Fink JK
Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
[No Abstract] [Full Text] [Related]
4. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
5. Excellent response to the clinical treatment of tophaceous gout.
Caldas CA; Fuller R
Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of hypouricemic effect of benzbromarone.
Sinclair DS; Fox IH
J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
[TBL] [Abstract][Full Text] [Related]
7. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
Perez-Ruiz F; Calabozo M; Erauskin GG; Ruibal A; Herrero-Beites AM
Arthritis Rheum; 2002 Dec; 47(6):610-3. PubMed ID: 12522834
[TBL] [Abstract][Full Text] [Related]
8. Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Yan F; Xue X; Lu J; Dalbeth N; Qi H; Yu Q; Wang C; Sun M; Cui L; Liu Z; He Y; Yuan X; Chen Y; Cheng X; Ma L; Li H; Ji A; Hu S; Ran Z; Terkeltaub R; Li C
Arthritis Rheumatol; 2022 Dec; 74(12):2015-2023. PubMed ID: 35795968
[TBL] [Abstract][Full Text] [Related]
9. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
12. Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
Sakaguchi S
Arthritis Rheumatol; 2021 Feb; 73(2):231. PubMed ID: 32892502
[No Abstract] [Full Text] [Related]
13. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of gout with the combination of xanthine oxidase inhibitors and uricosuric agents].
Delbarre F; Saporta L; de Géry A; Jabre E
Rev Rhum Mal Osteoartic; 1970; 37(6):443-50. PubMed ID: 5453852
[No Abstract] [Full Text] [Related]
15. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
[TBL] [Abstract][Full Text] [Related]
16. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.
Richette P; Frazier A; Bardin T
Curr Opin Rheumatol; 2015 Mar; 27(2):170-4. PubMed ID: 25594854
[TBL] [Abstract][Full Text] [Related]
17. [The effect of benzbromaron in gout patients with limited kidney function].
Kuzmits R; Bresnik W; Müller MM
Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
[TBL] [Abstract][Full Text] [Related]
18. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
19. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
[TBL] [Abstract][Full Text] [Related]
20. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
Liu S; Perez-Ruiz F; Miner JN
Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
